
    
      With growing demands on limited health care budgets, optimal resource allocation in HF
      patients is essential. Although NT pro BNP is proposed to be effective for the evaluation and
      management patients with heart failure, no data exist about cost-effectiveness analysis that
      are based on practice patterns endorsed by universal coverage systems in Indonesia (Jaminan
      Kesehatan Nasional). Because NT-proBNP therapy guidance in HF is believed to create
      additional costs, it is not yet broadly applicable. Its why we need to elaborate this issue.
    
  